All In Biotech

Drug Trial Radar · NCT07681076

Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

A Phase 4, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Twice Daily Xanomeline/Trospium Chloride (KarXT) With Prophylactic and PRN Antiemetic Use in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study looks at how to reduce nausea and vomiting in people taking KarXT which is used to treat mental health conditions like schizophrenia. KarXT can cause stomach-related side effects, especially in the first couple of weeks. In this study, healthy volunteers will take KarXT along with anti-nausea medication, either regularly (to prevent symptoms) or as needed. The goal is to see how well these strategies help reduce nausea and vomiting and how safe the combination is. The results will help doctors better manage side effects and make treatment more comfortable for patients starting KarXT.

Conditions

  • Healthy Volunteers

Interventions

  • KarXTDrug

    Specified dose on specified days

  • TrimethobenzamideDrug

    Specified dose on specified days

  • OndansetronDrug

    Specified dose on specified days

  • MeclizineDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 21

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS

    Los Alamitos, California · Recruiting

  • CenExel RCA - Hollywood

    Hollywood, Florida · Recruiting

  • Atlanta Center for Medical Research - CenExel ACMR - PPDS

    Atlanta, Georgia · Recruiting

  • iResearch Atlanta - CenExel - PPDS

    Decatur, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.